241 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
SGEN Seattle Genetics, Inc. $76.15 $12.09B Buy
Article Searches
Affimed: Promising, Undervalued Immunotherapy Play With Multiple Catalysts Ahead https://seekingalpha.com/article/4226864-affimed-promising-undervalued-immunotherapy-play-multiple-catalysts-ahead?source=feed_sector_healthcare Dec 06, 2018 - Impressive list of collaborators, including Genentech, Merck, Nektar Therapeutics, Columbia University and MD Anderson Cancer Center; and strong balance sheet with ~$139 million in cash.Breakout ASH20
Cancer Research Highlight: BeiGene Also Showed Up At ASH With Potentially Crucial Checkpoint Data https://seekingalpha.com/article/4226368-cancer-research-highlight-beigene-also-showed-ash-potentially-crucial-checkpoint-data?source=feed_sector_healthcare Dec 05, 2018 -
FDA OKs Seattle Genetics' Adcetris for PTCL; shares up 2% https://seekingalpha.com/news/3410545-fda-oks-seattle-genetics-adcetris-ptcl-shares-2-percent?source=feed_news_all Nov 16, 2018 - Under its Real-Time Oncology Review (RTOR) program, the FDA approves Seattle Genetics' (SGEN +2.2%) ADCETRIS (brentuximab vedotin), combined with chemo, for the treatment of adult patients wit
ProShares Nasdaq Biotech ETF And Holdings Review For Buys https://seekingalpha.com/article/4222496-proshares-nasdaq-biotech-etf-holdings-review-buys?source=feed_tag_etf_portfolio_strategy Nov 15, 2018 - Most Biotech Developers group are in a pullback mode, reflecting the market’s current election uncertainties.The Direxion Daily S&P Biotech Bull 3X ETF (LABU) holds many of these stocks and is an effi
Seattle Genetics' Adcetris a Breakthrough Therapy for first-line T-cell lymphomas; shares up 2% premarket https://seekingalpha.com/news/3410035-seattle-genetics-adcetris-breakthrough-therapy-first-line-t-cell-lymphomas-shares-2-percent?source=feed_news_all Nov 15, 2018 - Seattle Genetics (NASDAQ:SGEN) is up 2% premarket, albeit on only 200 shares, in response to its announcement that the FDA has granted Breakthrough Therapy status for ADCETRIS (brentuximab vedotin) f
Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark http://www.zacks.com/stock/news/332025/seattle-genetics-sgen-q3-loss-in-line-sales-top-mark?cid=CS-ZC-FT-332025 Oct 26, 2018 - Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.
Seattle Genetics Inc (SGEN) Q3 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2018/10/26/seattle-genetics-inc-sgen-q3-2018-earnings-confere.aspx?source=iedfolrf0000001 Oct 26, 2018 - SGEN earnings call for the period ending September 30, 2018.
Seattle Genetics (SGEN) Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4214704-seattle-genetics-sgen-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Oct 25, 2018 - Seattle Genetics, Inc. (NASDAQ:SGEN)Q3 2018 Earnings CallOctober 25, 2018 4:30 pm ETExecutivesPeggy Pinkston - Seattle Genetics, Inc.Clay B. Siegall - Seattle Genetics, Inc.Darren S. Cline - Seattle G
After-Hours Report: MAT +8.4%, CMG +5%, INTC +3.4%, MHK -18.3%, SGEN -15.9%, FLEX -15.7% on earnings/guidance http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=NS20181025165857AfterHoursReport Oct 25, 2018 - Stocks staged a welcome rebound on Thursday, but not before giving up some gains in the last hour. R
Seattle Genetics' Adcetris OK'd in Japan for first-line CD30+ Hodgkin lymphoma https://seekingalpha.com/news/3392154-seattle-genetics-adcetris-okd-japan-first-line-cd30-plus-hodgkin-lymphoma?source=feed_news_all Sep 21, 2018 - The Japanese Ministry of Health, Labor and Welfare approves Seattle Genetics' (SGEN -1.4%) ADCETRIS (brentuximab vedotin), combined with chemo agents doxorubicin, vinblastine and dacarbazine, for the

Pages: 123456...25

Page 1>

Related Companies

Name Exchange Price Mkt Cap
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NYSE $37.42 $8.5B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
BLUE bluebird bio, Inc. NASDAQ $137.25 $7.43B
TECH Bio-Techne Corp NASDAQ $196.8 $7.43B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Seattle Genetics
SGEN - Google Finance https://www.google.com/finance?q=SGEN Industry related info and international coverage Summary News
SGEN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=SGEN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options